Stefan Verlohren
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Stefan Verlohren has a total of 449 co-authors. Here are the top co-authors by number of shared publications:
Wolfgang Henrich
Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Obstetrics, Berlin, Germany
23 shared publications- Florian Herse
Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
15 shared publications Holger Stepan
Department of Obstetrics, University Hospital Leipzig, Leipzig, Germany
14 shared publicationsHarald Zeisler
12 shared publicationsAlberto Galindo
Fetal Medicine Unit - Maternal and Child Health and Development Network, Department of Obstetrics and Gynaecology, University Hospital 12 de Octubre, Instituto de Investigación Hospital 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain
10 shared publications- Dominik Nikolaus Müller
Experimental and Clinical Research Center (ECRC) A Cooperation of Charité – Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine (MDC) Berlin Germany
10 shared publications
Latest Publications
- 24 August 2026
- Published by Wiley in American Journal of Reproductive Immunology
- Vol. 96 (2) , e70299
Therapeutic Interventions for Preeclampsia: Integrating Placental and Maternal Perspectives
Preeclampsia (PE), a hypertensive disorder of pregnancy, is one of the leading causes of maternal and fetal mortality worldwide. Beyond the immediate pregnancy impact, it is also associated with increased long‐term risks in both the mother and the offspring. Currently, no causal therapy exists. Consequently, the complex and heterogeneous nature of PE necessitates the exploration of novel therapeutic targets to improve maternal and fetal outcomes. This review summarizes models of pathogenesis in PE, particularly the two‐stage model of the development of PE, where the placenta is suggested to be the main source of the disease, and the postulation that PE is a result of dysfunction of the maternal cardiovascular system. We explore novel therapeutic approaches, considering the underlying mechanisms such as galectin‐13, placental growth factor, therapeutic plasma exchange (TPE), trophoblast‐targeted nanomedicine, gene therapy, nitric oxide donors, endothelin receptor antagonists, and mesenchymal stem cells. Challenges in translating preclinical findings to clinical practice, including animal model limitations and ethical considerations, are discussed. Finally, this review integrates current treatment options, discusses their limitations, highlights ethical considerations, and outlines future directions for PE therapeutics, emphasizing the need for personalized therapeutic strategies.
- 24 August 2026
- Published by Wiley in American Journal of Reproductive Immunology
- Vol. 96 (2) , e70299
Therapeutic Interventions for Preeclampsia: Integrating Placental and Maternal Perspectives
Preeclampsia (PE), a hypertensive disorder of pregnancy, is one of the leading causes of maternal and fetal mortality worldwide. Beyond the immediate pregnancy impact, it is also associated with increased long‐term risks in both the mother and the offspring. Currently, no causal therapy exists. Consequently, the complex and heterogeneous nature of PE necessitates the exploration of novel therapeutic targets to improve maternal and fetal outcomes. This review summarizes models of pathogenesis in PE, particularly the two‐stage model of the development of PE, where the placenta is suggested to be the main source of the disease, and the postulation that PE is a result of dysfunction of the maternal cardiovascular system. We explore novel therapeutic approaches, considering the underlying mechanisms such as galectin‐13, placental growth factor, therapeutic plasma exchange (TPE), trophoblast‐targeted nanomedicine, gene therapy, nitric oxide donors, endothelin receptor antagonists, and mesenchymal stem cells. Challenges in translating preclinical findings to clinical practice, including animal model limitations and ethical considerations, are discussed. Finally, this review integrates current treatment options, discusses their limitations, highlights ethical considerations, and outlines future directions for PE therapeutics, emphasizing the need for personalized therapeutic strategies.
- Open Access
- 19 May 2026
- Published by Springer Nature in Reviews in Endocrine and Metabolic Disorders
- Vol. 27 (4) , 1-22
Maternal obesity and the metabolic syndrome in reproductive health: assessing incretin-based interventions
The global epidemic of overweight and obesity threatens gynecological and reproductive health, necessitating effective therapeutic strategies to improve maternal and fetal long-term health outcomes. This review provides an overview of weight loss interventions and discusses their use in the context of gestation, such as surgical interventions and anti-obesity medications. As the interest in incretin-based therapies has risen substantially, we discuss how incretin-based therapies, including glucagon-like peptide-1 (GLP-1) receptor agonists and GLP-1 receptor agonists and glucose-dependent insulinotropic polypeptide (GIP) dual agonists, might improve reproductive function and could interact with the physiological metabolic changes ensuring a healthy pregnancy. These metabolic adaptations during pregnancy arise from the integration of insulin signaling, lipid metabolism, placental endocrine function, mitochondrial remodeling and inflammatory regulation. Furthermore, we consider not only short-term consequences of maternal overweight and obesity but also focus on fetal long-term health trajectories following pregnancy-related metabolic disorders, as maternal obesity and gestational weight gain are considered risk factors for childhood obesity and overweight.
- 19 May 2026
- Published by Springer Nature in Reviews in Endocrine and Metabolic Disorders
- Vol. 27 (4) , 1-22
Open AccessMaternal obesity and the metabolic syndrome in reproductive health: assessing incretin-based interventions
The global epidemic of overweight and obesity threatens gynecological and reproductive health, necessitating effective therapeutic strategies to improve maternal and fetal long-term health outcomes. This review provides an overview of weight loss interventions and discusses their use in the context of gestation, such as surgical interventions and anti-obesity medications. As the interest in incretin-based therapies has risen substantially, we discuss how incretin-based therapies, including glucagon-like peptide-1 (GLP-1) receptor agonists and GLP-1 receptor agonists and glucose-dependent insulinotropic polypeptide (GIP) dual agonists, might improve reproductive function and could interact with the physiological metabolic changes ensuring a healthy pregnancy. These metabolic adaptations during pregnancy arise from the integration of insulin signaling, lipid metabolism, placental endocrine function, mitochondrial remodeling and inflammatory regulation. Furthermore, we consider not only short-term consequences of maternal overweight and obesity but also focus on fetal long-term health trajectories following pregnancy-related metabolic disorders, as maternal obesity and gestational weight gain are considered risk factors for childhood obesity and overweight.
- Open Access
- 26 March 2026
- Published by Elsevier in Pregnancy Hypertension
- Vol. 44, 101457
Internal and external validation of a machine learning algorithm to detect preeclampsia-related adverse outcomes in high-risk pregnancies
- 26 March 2026
- Published by Elsevier in Pregnancy Hypertension
- Vol. 44, 101457
Open AccessInternal and external validation of a machine learning algorithm to detect preeclampsia-related adverse outcomes in high-risk pregnancies
- Open Access
- 6 February 2026
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 313 (1) , 81
Validation of a machine-learning-based algorithm to predict preeclampsia-related adverse outcomes on a real-world dataset
Purpose: Preeclampsia is a major obstetric disorder. Machine learning (ML) models incorporating angiogenic biomarkers show promise in predicting related adverse outcomes, but refinement is needed for clinical use. This study aimed to reduce features to a clinically meaningful set and to develop and validate predictive endpoints for preeclampsia-associated outcomes. Methods: A model with a reduced feature set was derived from a training cohort of 1,634 patients (2, 412 visits) and then tested on a validation cohort of 402 patients (540 visits). Three machine learning models were developed to predict (1) adverse outcomes overall, (2) delivery within 14 days before 34 weeks of gestation, and (3) delivery within 7 days after 34 weeks, using 13 features versus 114 originally. Results: Reduced-feature models demonstrated comparable accuracy to original models across all endpoints. Model 1 (any adverse outcome) achieved an Area Under the Receiver Operating Characteristic Curve (AUROC) of 0.92 (95% CI: 0.88–0.96) in training and 0.89 (95% CI: 0.84–0.93, p = 0.31) in the validation cohort, respectively. For delivery within 14 days, the AUROC was 0.92 (95% CI: 0.87–0.96) in training and 0.85 (95% CI: 0.78–0.92) in validation ( p = 0.13). Delivery within 7 days showed AUROCs of 0.79 (95% CI: 0.70–0.87) and 0.80 (95% CI: 0.75–0.85) ( p = 0.78). Conclusion: A machine learning model with a significantly reduced number of features can accurately predict clinically relevant preeclampsia outcomes. The identified endpoints (timing of delivery and adverse events) could support clinical decision-making and help reduce maternal and neonatal morbidity and mortality.
- 6 February 2026
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 313 (1) , 81
Open AccessValidation of a machine-learning-based algorithm to predict preeclampsia-related adverse outcomes on a real-world dataset
Purpose: Preeclampsia is a major obstetric disorder. Machine learning (ML) models incorporating angiogenic biomarkers show promise in predicting related adverse outcomes, but refinement is needed for clinical use. This study aimed to reduce features to a clinically meaningful set and to develop and validate predictive endpoints for preeclampsia-associated outcomes. Methods: A model with a reduced feature set was derived from a training cohort of 1,634 patients (2, 412 visits) and then tested on a validation cohort of 402 patients (540 visits). Three machine learning models were developed to predict (1) adverse outcomes overall, (2) delivery within 14 days before 34 weeks of gestation, and (3) delivery within 7 days after 34 weeks, using 13 features versus 114 originally. Results: Reduced-feature models demonstrated comparable accuracy to original models across all endpoints. Model 1 (any adverse outcome) achieved an Area Under the Receiver Operating Characteristic Curve (AUROC) of 0.92 (95% CI: 0.88–0.96) in training and 0.89 (95% CI: 0.84–0.93, p = 0.31) in the validation cohort, respectively. For delivery within 14 days, the AUROC was 0.92 (95% CI: 0.87–0.96) in training and 0.85 (95% CI: 0.78–0.92) in validation ( p = 0.13). Delivery within 7 days showed AUROCs of 0.79 (95% CI: 0.70–0.87) and 0.80 (95% CI: 0.75–0.85) ( p = 0.78). Conclusion: A machine learning model with a significantly reduced number of features can accurately predict clinically relevant preeclampsia outcomes. The identified endpoints (timing of delivery and adverse events) could support clinical decision-making and help reduce maternal and neonatal morbidity and mortality.
- Open Access
- 21 January 2026
- Published by Elsevier in Neuromuscular Disorders
- Vol. 60, 106354
Preemptive immunotherapy for fetal acetylcholine receptor antibody disorder (FARAD): from recurrent pregnancy losses to a healthy infant - a case report
- 21 January 2026
- Published by Elsevier in Neuromuscular Disorders
- Vol. 60, 106354
Open AccessPreemptive immunotherapy for fetal acetylcholine receptor antibody disorder (FARAD): from recurrent pregnancy losses to a healthy infant - a case report
- Open Access
- 16 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (18) , 9015
Circulating Plasma Syncytin-1 mRNA in Preeclampsia—A Pilot Study
The endogenous human retroviral protein syncytin-1 is vital for placental integrity via syncytiotrophoblast formation. Preeclampsia has been associated with reduced placental syncytin-1 expression. The goal of the prospective pilot study was to investigate the role of circulating fetal syncytin-1 mRNA in women with and without preeclampsia (PE). We therefore determined syncytin-1 mRNA in maternal plasma of n = 26 women without and n = 43 women with PE with quantitative real-time PCR. Median circulating syncytin-1 mRNA concentrations were significantly lower in women with PE [1 217 050 copies; IQR 610 900–1 482 069] vs. those without PE [1 992 739 copies; IQR 1 616 811–3 126 225], p < 0.001. The area under the receiver operating curve used to diagnose PE at the time of delivery was 0.913 (95% CI: 0.850–0.977). Sub-analysis of patients with PE at sampling and patients who later developed PE vs. gestational-age-matched controls yielded a diagnostic accuracy of fetal syncytin-1 expression with an AUC of 0.962 (95% CI 0.877–1.000) and a predictive accuracy of 0.924 (95% CI 0.842–0.983). Quantification of the fetal syncytin-1 expression in maternal plasma might be used as a diagnostic and predictive tool in PE.
- 16 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (18) , 9015
Open AccessCirculating Plasma Syncytin-1 mRNA in Preeclampsia—A Pilot Study
The endogenous human retroviral protein syncytin-1 is vital for placental integrity via syncytiotrophoblast formation. Preeclampsia has been associated with reduced placental syncytin-1 expression. The goal of the prospective pilot study was to investigate the role of circulating fetal syncytin-1 mRNA in women with and without preeclampsia (PE). We therefore determined syncytin-1 mRNA in maternal plasma of n = 26 women without and n = 43 women with PE with quantitative real-time PCR. Median circulating syncytin-1 mRNA concentrations were significantly lower in women with PE [1 217 050 copies; IQR 610 900–1 482 069] vs. those without PE [1 992 739 copies; IQR 1 616 811–3 126 225], p < 0.001. The area under the receiver operating curve used to diagnose PE at the time of delivery was 0.913 (95% CI: 0.850–0.977). Sub-analysis of patients with PE at sampling and patients who later developed PE vs. gestational-age-matched controls yielded a diagnostic accuracy of fetal syncytin-1 expression with an AUC of 0.962 (95% CI 0.877–1.000) and a predictive accuracy of 0.924 (95% CI 0.842–0.983). Quantification of the fetal syncytin-1 expression in maternal plasma might be used as a diagnostic and predictive tool in PE.
- Top Cited PapersOpen Access
- 1 May 2025
- Published by Wolters Kluwer Health in Hypertension
- Vol. 82 (5) , 787-799
Senescent Syncytiotrophoblast Secretion During Early Onset Preeclampsia
BACKGROUND: Preeclampsia is a severe hypertensive disorder in pregnancy that causes preterm delivery, maternal and fetal morbidity, mortality, and life-long sequelae. Understanding the pathogenesis of preeclampsia is a critical first step toward protecting mother and child from this syndrome and increased risk of cardiovascular disease later in life. However, effective early predictive tests and therapies for preeclampsia are scarce. METHODS: To identify novel markers and signaling pathways for early onset preeclampsia, we profiled human maternal-fetal interface units (fetal villi and maternal decidua) from early onset preeclampsia and healthy controls using single-nucleus RNA sequencing combined with spatial transcriptomics. The placental syncytiotrophoblast is in direct contact with maternal blood and forms the barrier between fetal and maternal circulation. RESULTS: We identified different transcriptomic states of the endocrine syncytiotrophoblast nuclei with patterns of dysregulation associated with a senescence-associated secretory phenotype and a spatial dysregulation of senescence in the placental trophoblast layer. Elevated senescence markers were validated in placental tissues of clinical multicenter cohorts. Importantly, several secreted senescence-associated secretory phenotype factors were elevated in maternal blood already in the first trimester. We verified the secreted senescence markers, PAI-1 (plasminogen activator inhibitor 1) and activin A, as identified in our single-nucleus RNA sequencing model as predictive markers before clinical preeclampsia diagnosis. CONCLUSIONS: This indicates that increased syncytiotrophoblast senescence appears weeks before clinical manifestation of early onset preeclampsia, suggesting that the dysregulated preeclamptic placenta starts with higher cell maturation resulting in premature and increased senescence-associated secretory phenotype release. These senescence-associated secretory phenotype markers may serve as an additional early diagnostic tool for this syndrome.
- 1 May 2025
- Published by Wolters Kluwer Health in Hypertension
- Vol. 82 (5) , 787-799
Top Cited PapersOpen AccessSenescent Syncytiotrophoblast Secretion During Early Onset Preeclampsia
BACKGROUND: Preeclampsia is a severe hypertensive disorder in pregnancy that causes preterm delivery, maternal and fetal morbidity, mortality, and life-long sequelae. Understanding the pathogenesis of preeclampsia is a critical first step toward protecting mother and child from this syndrome and increased risk of cardiovascular disease later in life. However, effective early predictive tests and therapies for preeclampsia are scarce. METHODS: To identify novel markers and signaling pathways for early onset preeclampsia, we profiled human maternal-fetal interface units (fetal villi and maternal decidua) from early onset preeclampsia and healthy controls using single-nucleus RNA sequencing combined with spatial transcriptomics. The placental syncytiotrophoblast is in direct contact with maternal blood and forms the barrier between fetal and maternal circulation. RESULTS: We identified different transcriptomic states of the endocrine syncytiotrophoblast nuclei with patterns of dysregulation associated with a senescence-associated secretory phenotype and a spatial dysregulation of senescence in the placental trophoblast layer. Elevated senescence markers were validated in placental tissues of clinical multicenter cohorts. Importantly, several secreted senescence-associated secretory phenotype factors were elevated in maternal blood already in the first trimester. We verified the secreted senescence markers, PAI-1 (plasminogen activator inhibitor 1) and activin A, as identified in our single-nucleus RNA sequencing model as predictive markers before clinical preeclampsia diagnosis. CONCLUSIONS: This indicates that increased syncytiotrophoblast senescence appears weeks before clinical manifestation of early onset preeclampsia, suggesting that the dysregulated preeclamptic placenta starts with higher cell maturation resulting in premature and increased senescence-associated secretory phenotype release. These senescence-associated secretory phenotype markers may serve as an additional early diagnostic tool for this syndrome.
- 16 April 2025
- Published by Springer Nature
- p. 625-645
Prädiktiver Ultraschall, Screening und Vorhersage für Präeklampsie und fetale Wachstumsrestriktion im II. und III. Trimester
- 16 April 2025
- Published by Springer Nature
- p. 625-645
Prädiktiver Ultraschall, Screening und Vorhersage für Präeklampsie und fetale Wachstumsrestriktion im II. und III. Trimester
- Open Access
- 16 June 2023
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 309 (5) , 1971-1980
Accuracy of prenatal detection of facial clefts and relation between facial clefts, additional malformations and chromosomal abnormalities: a large referral-center cohort
Purpose: Facial clefts belong to the most common congenital malformations and their prenatal diagnosis is a constant challenge. The aim of this study was to determine the accuracy of prenatal ultrasound in correctly classifying facial clefts. Furthermore, we aimed to specify the distribution of the type of clefts and underlying genetic conditions. Methods: All fetuses seen with suspected facial cleft in the Department of Obstetrics, Charité – Universitätsmedizin Berlin during a period of 23 years (1999–2022) were included in this retrospective study. Clefts were classified according to the classification of Nyberg. All additional prenatal findings were assessed and correlated with the outcome. The accuracy of prenatal diagnosis was assessed. Results: 292 patients were included in the study. The most common type of clefts were unilateral cleft lip and palate (CL-P) (53.6%) and bilateral CL-P (30.6%), followed by CL (8.1%), CP (5.1%) and median CL-P (2.6%). The overall pre- and postnatal concordance rate corresponding to a correct prenatal diagnosis was high, 88.9%, ranging from 73.7% (CL) to 93.7% (unilateral CL-P). Most of the median clefts (95.2%) and CP (93.3%) were associated with other sonographic abnormalities, as well as 52.2% of bilateral CL-P. Chromosomal abnormalities, mostly trisomy 13 and trisomy 18, were observed in in the median CL-P (47.6%), bilateral CL-P (31.1%) and CP (26.7%) groups, in contrast to the CL (9.1%) and unilateral CL-P (12.9%) groups. It was exceptional to have a chromosomal abnormality without additional malformations (4.8%). The mortality rate including one late miscarriage, 5 IUFD’s, 74 TOPs and 6 palliative cares at birth was 29.8%, particularly high for median clefts (90.5%). Conclusion: Prenatal ultrasound exhibited a high accuracy to assess the type of facial clefts with an average rate of 88.9% (73.7%–93.7%) and a concordance rate of up to 93.7%, depending on the type of cleft. The search for additional malformations as well as clarifying underlying genetic conditions is essential. This allows for a targeted counseling of the parents and to best prepare for postnatal care, including surgery by the maxillofacial team.
- 16 June 2023
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 309 (5) , 1971-1980
Open AccessAccuracy of prenatal detection of facial clefts and relation between facial clefts, additional malformations and chromosomal abnormalities: a large referral-center cohort
Purpose: Facial clefts belong to the most common congenital malformations and their prenatal diagnosis is a constant challenge. The aim of this study was to determine the accuracy of prenatal ultrasound in correctly classifying facial clefts. Furthermore, we aimed to specify the distribution of the type of clefts and underlying genetic conditions. Methods: All fetuses seen with suspected facial cleft in the Department of Obstetrics, Charité – Universitätsmedizin Berlin during a period of 23 years (1999–2022) were included in this retrospective study. Clefts were classified according to the classification of Nyberg. All additional prenatal findings were assessed and correlated with the outcome. The accuracy of prenatal diagnosis was assessed. Results: 292 patients were included in the study. The most common type of clefts were unilateral cleft lip and palate (CL-P) (53.6%) and bilateral CL-P (30.6%), followed by CL (8.1%), CP (5.1%) and median CL-P (2.6%). The overall pre- and postnatal concordance rate corresponding to a correct prenatal diagnosis was high, 88.9%, ranging from 73.7% (CL) to 93.7% (unilateral CL-P). Most of the median clefts (95.2%) and CP (93.3%) were associated with other sonographic abnormalities, as well as 52.2% of bilateral CL-P. Chromosomal abnormalities, mostly trisomy 13 and trisomy 18, were observed in in the median CL-P (47.6%), bilateral CL-P (31.1%) and CP (26.7%) groups, in contrast to the CL (9.1%) and unilateral CL-P (12.9%) groups. It was exceptional to have a chromosomal abnormality without additional malformations (4.8%). The mortality rate including one late miscarriage, 5 IUFD’s, 74 TOPs and 6 palliative cares at birth was 29.8%, particularly high for median clefts (90.5%). Conclusion: Prenatal ultrasound exhibited a high accuracy to assess the type of facial clefts with an average rate of 88.9% (73.7%–93.7%) and a concordance rate of up to 93.7%, depending on the type of cleft. The search for additional malformations as well as clarifying underlying genetic conditions is essential. This allows for a targeted counseling of the parents and to best prepare for postnatal care, including surgery by the maxillofacial team.
- 21 February 2023
- Published by S. Karger AG in Fetal Diagnosis and Therapy
- Vol. 50 (3) , 215-224
Comparison of the Soluble fms-Like Tyrosine Kinase 1/Placental Growth Factor Ratio Alone versus a Multi-Marker Regression Model for the Prediction of Preeclampsia-Related Adverse Outcomes after 34 Weeks of Gestation
Introduction: The objective of this retrospective study was to compare the predictive performance of the soluble fms-like tyrosine kinase 1 (sFlt-1)/placental growth factor (PlGF) ratio alone or in a multi-marker regression model for preeclampsia-related maternal and/or fetal adverse outcomes in women >34 weeks of gestation. Methods: We analyzed the data collected from 655 women with suspected preeclampsia. Adverse outcomes were predicted by multivariable and univariable logistic regression models. The outcome of patients was evaluated within 14 days after presentation with signs and symptoms of preeclampsia or diagnosed preeclampsia. Results: The full model integrating available, standard clinical information and the sFlt-1/PlGF ratio had the best predictive performance for adverse outcomes with an AUC of 72.6%, which corresponds to a sensitivity of 73.3% and specificity of 66.0%. The positive predictive value of the full model was 51.4%, and the negative predictive value was 83.5%. 24.5% of patients, who did not experience adverse outcomes but were classified as high risk by sFlt-1/PlGF ratio (≥38), were correctly classified by the regression model. The sFlt-1/PlGF ratio alone had a significantly lower AUC of 65.6%. Conclusions: Integrating angiogenic biomarkers in a regression model improved the prediction of preeclampsia-related adverse outcomes in women at risk after 34 weeks of gestation.
- 21 February 2023
- Published by S. Karger AG in Fetal Diagnosis and Therapy
- Vol. 50 (3) , 215-224
Comparison of the Soluble fms-Like Tyrosine Kinase 1/Placental Growth Factor Ratio Alone versus a Multi-Marker Regression Model for the Prediction of Preeclampsia-Related Adverse Outcomes after 34 Weeks of Gestation
Introduction: The objective of this retrospective study was to compare the predictive performance of the soluble fms-like tyrosine kinase 1 (sFlt-1)/placental growth factor (PlGF) ratio alone or in a multi-marker regression model for preeclampsia-related maternal and/or fetal adverse outcomes in women >34 weeks of gestation. Methods: We analyzed the data collected from 655 women with suspected preeclampsia. Adverse outcomes were predicted by multivariable and univariable logistic regression models. The outcome of patients was evaluated within 14 days after presentation with signs and symptoms of preeclampsia or diagnosed preeclampsia. Results: The full model integrating available, standard clinical information and the sFlt-1/PlGF ratio had the best predictive performance for adverse outcomes with an AUC of 72.6%, which corresponds to a sensitivity of 73.3% and specificity of 66.0%. The positive predictive value of the full model was 51.4%, and the negative predictive value was 83.5%. 24.5% of patients, who did not experience adverse outcomes but were classified as high risk by sFlt-1/PlGF ratio (≥38), were correctly classified by the regression model. The sFlt-1/PlGF ratio alone had a significantly lower AUC of 65.6%. Conclusions: Integrating angiogenic biomarkers in a regression model improved the prediction of preeclampsia-related adverse outcomes in women at risk after 34 weeks of gestation.